

Paul A Thomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3554271/publications.pdf>

Version: 2024-02-01

68
papers

2,701
citations

279798

23
h-index

189892

50
g-index

75
all docs

75
docs citations

75
times ranked

3372
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 763-776.	6.4	36
2	High SUVmax on routine pre-operative FDG-PET predicts early recurrence in pancreatic and peri-ampullary cancer. <i>Hpb</i> , 2022, , .	0.3	3
3	Pituitary Metastasis of Renal Cell Carcinoma Characterized by 18F-PSMA-1007 PET/CT. <i>Clinical Nuclear Medicine</i> , 2022, Publish Ahead of Print, .	1.3	2
4	[18F]GE-180 PET/CT assessment of enterocytic translocator protein (TSPO) over-expression: a pilot study in gastrointestinal GVHD. <i>Bone Marrow Transplantation</i> , 2022, 57, 517-519.	2.4	3
5	The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 66.e1-66.e9.	1.6	20
6	Reduced cortical cholinergic innervation measured using [18F]-FEOBV PET imaging correlates with cognitive decline in mild cognitive impairment. <i>NeuroImage: Clinical</i> , 2022, 34, 102992.	2.7	14
7	Positron emission tomography and magnetic resonance imaging of the brain in experimental human malaria, a prospective cohort study. <i>Scientific Reports</i> , 2022, 12, 5696.	3.3	1
8	Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 276.e1-276.e9.	1.6	8
9	68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 477-482.	6.4	54
10	A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and Immunotherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma. <i>Radiation Oncology</i> , 2021, 16, 69.	2.7	12
11	Positron emission tomography and magnetic resonance imaging in experimental human malaria to identify organ-specific changes in morphology and glucose metabolism: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003567.	8.4	6
12	Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4495-4507.	6.4	41
13	Abstract CT101: Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma. , 2021, , .		0
14	Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review. <i>Advances in Urology</i> , 2021, 2021, 1-9.	1.3	13
15	The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. <i>European Urology</i> , 2021, 80, 682-689.	1.9	181
16	Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer. <i>Contrast Media and Molecular Imaging</i> , 2021, 2021, 1-12.	0.8	2
17	Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging. <i>EJNMMI Research</i> , 2021, 11, 128.	2.5	6
18	PET Imaging Quantifying ⁶⁸ Ga-PSMA-11 Uptake in Metastatic Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1576-1579.	5.0	15

#	ARTICLE	IF	CITATIONS
19	Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. <i>Lancet, The</i> , 2020, 395, 1208-1216.	13.7	1,108
20	Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma. <i>Theranostics</i> , 2020, 10, 4116-4133.	10.0	23
21	Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of glioma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 650-656.	1.8	12
22	Abstract CT063: Preliminary findings of a Phase I safety and bioimaging trial of KB004 (ifabotuzumab) in patients with glioblastoma. <i>Cancer Research</i> , 2019, 79, CT063-CT063.	0.9	5
23	Sifting through the surfeit of neuroinflammation tracers. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 204-224.	4.3	92
24	Targeted Molecular Imaging of Translocator Protein (TSPO) Using 18FGE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD). <i>Blood</i> , 2018, 132, 3397-3397.	1.4	0
25	Design and utilisation of protocols to characterise dynamic PET uptake of two tracers using basis pursuit. <i>Physics in Medicine and Biology</i> , 2017, 62, 4897-4916.	3.0	11
26	PET motion correction in context of integrated PET/MR: Current techniques, limitations, and future projections. <i>Medical Physics</i> , 2017, 44, e430-e445.	3.0	31
27	Intense Uptake in Amyloidosis of the Seminal Vesicles on 68Ga-PSMA PET Mimicking Locally Advanced Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2017, 42, 147-148.	1.3	20
28	Federated optimisation of kinetic analysis problems. <i>Medical Image Analysis</i> , 2017, 35, 116-132.	11.6	0
29	The utility of FDG-PET in complex neurological conditions. <i>Internal Medicine Journal</i> , 2017, 47, 1460-1462.	0.8	1
30	The CHAPPP study: Changing care with PSMA-PET for prostate cancer – A retrospective study of the role of PSMA imaging in altering treatment pathways.. <i>Journal of Clinical Oncology</i> , 2017, 35, 13-13.	1.6	0
31	The CHAPPP study: Changing care with PSMA-PET for prostate cancer – A retrospective study of the role of PSMA imaging in altering treatment pathways.. <i>Journal of Clinical Oncology</i> , 2017, 2017, 13-13.	1.6	0
32	Rectal Carcinoma on 68Ga-PSMA PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, e167-e168.	1.3	72
33	Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease. <i>Pathology</i> , 2016, 48, 613-616.	0.6	27
34	Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. <i>EJNMMI Research</i> , 2016, 6, 76.	2.5	104
35	Paget Disease. <i>Clinical Nuclear Medicine</i> , 2016, 41, 699-700.	1.3	30
36	A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non-contrast CT scanning on the management of operable pancreatic and periampullary cancers. <i>Hpb</i> , 2015, 17, 624-631.	0.3	22

#	ARTICLE	IF	CITATIONS
37	Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method. Journal of Medical Radiation Sciences, 2015, 62, 92-98.	1.5	35
38	Would you bet on ¹⁸F-PET? Evaluation of the significance of positive ¹⁸F-PET scan results post-microwave ablation for non-small cell lung cancer. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 702-712.	1.8	8
39	Unusual Soft Tissue Infiltrates With 18F-FDG Uptake in a Patient With Hairy Cell Leukemia. Clinical Nuclear Medicine, 2015, 40, e282-e284.	1.3	5
40	Hypoxia Imaging in Gliomas With 18F-Fluoromisonidazole PET: Toward Clinical Translation. Seminars in Nuclear Medicine, 2015, 45, 136-150.	4.6	60
41	Increasing feasibility and utility of 18 F-FDOPA PET for the management of glioma. Nuclear Medicine and Biology, 2015, 42, 788-795.	0.6	42
42	Early Prediction of Treatment Response in Advanced Gliomas with 18F-dopa Positron-Emission Tomography. Current Oncology, 2014, 21, 172-178.	2.2	8
43	Assessing local outcomes in heterogeneous gliomas. Journal of Physics: Conference Series, 2014, 489, 012073.	0.4	1
44	Dual acquisition of ¹⁸F-FMISO and ¹⁸F-FDOPA. Physics in Medicine and Biology, 2014, 59, 3925-3949.	3.0	7
45	Pharmacological Approaches That Slow Lymphatic Flow As a Snakebite First Aid. PLoS Neglected Tropical Diseases, 2014, 8, e2722.	3.0	25
46	Distance informed Track-Weighted Imaging (diTWI): A framework for sensitising streamline information to neuropathology. NeuroImage, 2014, 86, 60-66.	4.2	3
47	Amorphous Regions-of-Interest Projection Method for Simplified Longitudinal Comparison of Dynamic Regions in Cancer Imaging. IEEE Transactions on Biomedical Engineering, 2014, 61, 264-272.	4.2	1
48	Contribution of FDOPA PET to radiotherapy planning for advanced glioma. Journal of Physics: Conference Series, 2014, 489, 012028.	0.4	1
49	Economic analysis of FDG-PET guided management of the neck after primary chemoradiotherapy for node-positive head and neck squamous cell carcinoma. Head and Neck, 2013, 35, 1287-1294.	2.0	28
50	Automated Classification of Bone and Air Volumes for Hybrid PET-MRI Brain Imaging. , 2013, , .		8
51	Histogram matching for the generation of ventilation-perfusion difference images in SPECT lung scanning: A phantom study. Medical Physics, 2012, 39, 3026-3030.	3.0	0
52	Automatic Brain Tumour Segmentation in 18F-FDOPA PET Using PET/MRI Fusion. , 2011, , .		1
53	A pharmacological approach to first aid treatment for snakebite. Nature Medicine, 2011, 17, 809-811.	30.7	40
54	Tumor Thrombus in the Great Veins from Papillary Carcinoma of the Thyroid: 131I Scan Findings. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2527-2528.	3.6	13

#	ARTICLE	IF	CITATIONS
55	Transition from Planar to SPECT V/Q Scintigraphy: Rationale, Practicalities, and Challenges. <i>Seminars in Nuclear Medicine</i> , 2010, 40, 397-407.	4.6	36
56	Intractable hiccups causing avid FDG uptake in the muscles of respiration. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1901-1901.	6.4	0
57	A Comparison of Single-Photon Emission CT Lung Scintigraphy and CT Pulmonary Angiography for the Diagnosis of Pulmonary Embolism. <i>Chest</i> , 2009, 136, 1546-1553.	0.8	70
58	Merits of V/Q SPECT Scintigraphy Compared with CTPA in Imaging of Pulmonary Embolism. <i>Journal of Nuclear Medicine</i> , 2008, 49, 167-168.	5.0	16
59	Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). <i>European Heart Journal</i> , 2007, 28, 2998-3005.	2.2	174
60	Objective Analysis of Tomographic Ventilation-Perfusion Scintigraphy in Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 1173-1180.	5.6	51
61	Splenic Uptake of Tc-99m MDP in Patients With Hematologic Abnormalities Recently Treated With Chemotherapy. <i>Clinical Nuclear Medicine</i> , 1999, 24, 605-606.	1.3	4
62	Avid Ga-67 Uptake in Active Celiac Disease. <i>Clinical Nuclear Medicine</i> , 1999, 24, 465.	1.3	0
63	Outpatient management of patients with large multinodular goitres treated with fractionated radioiodine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 1465-1469.	6.4	27
64	Patient-related pitfalls and artifacts in nuclear medicine imaging. <i>Seminars in Nuclear Medicine</i> , 1996, 26, 295-307.	4.6	32
65	Paget's Disease of Bone. <i>New England Journal of Medicine</i> , 1996, 334, 160-160.	27.0	0
66	Avid In-111 Labeled WBC Accumulation in a Patient With Active Osteoarthritis of Both Knees. <i>Clinical Nuclear Medicine</i> , 1995, 20, 973-975.	1.3	10
67	Technetium-99m Sestamibi Marrow Uptake in a Patient With Myelodysplastic Syndrome. <i>Clinical Nuclear Medicine</i> , 1994, 19, 617-618.	1.3	3
68	In-111 Labeled Purified Granulocytes in the Diagnosis of Synthetic Vascular Graft Infections. <i>Clinical Nuclear Medicine</i> , 1994, 19, 1075-1078.	1.3	8